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        The brain occupies a privileged compartment in the body. 
This was fi  rst appreciated over a century ago by the demonstra-
tion that dyes injected into the blood did not extravasate into 
the brain. It is now apparent that this gatekeeping is a combi-
nation of highly selective active transport and, at the ultra-
structural level, a physical barrier localized to the tight junction 
complex between brain endothelial cell membranes (  Fig. 1  ; 
  Zlokovic, 2008  ). Many of the proteins comprising the tight 
junction, such as claudins (Cldns), occludin, and junctional 
adhesion molecules, have been identifi  ed, but the mechanisms 
governing their expression and assembly into a complex dur-
ing neurovascular development remain incomplete. Liebner 
et al. (see p.   409   of this issue) surmised that the Wnt signaling 
pathway, which is already prominent in brain development, 
was a good place to start. 
  As an initial step, they took advantage of a transgenic re-
porter mouse that monitors Wnt signaling activity via the ex-
pression of galactosidase. Reporter activity was readily observed 
in brain endothelial cells throughout the developing vascular 
network but dropped off sharply in postnatal animals and was 
nearly absent in adults. For a functional correlate, the authors 
used mice expressing both loss and gain of function mutants of 
Capillaries in the brain are especially selective in deter-
mining which blood-borne components gain access to 
neurons. The structural elements of this blood  –  brain bar-
rier (BBB) reside at the tight junction, an intercellular pro-
tein complex that welds together adjacent endothelial cell 
membranes in the microvasculature. In this issue, Liebner 
et al. (Liebner, S., M. Corada, T. Bangsow, J. Babbage, 
A. Taddei, C.J. Czupalla, M. Reis, A. Felici, H. Wolburg, 
M. Fruttiger, et al. 2008.   J. Cell Biol.   183: 409  –  417) re-
port that Wnt signaling plays an active role in the devel-
opment of the BBB by regulating expression of key protein 
constituents of the tight junction. Such mechanistic insight 
has implications for a variety of neuropathological states 
in which the BBB is breached.
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    -catenin, a key protein that is stabilized upon propagation of 
the Wnt signal. A marker of leaky brain vessels, plasmalemmal 
vesicle  –  associated protein-1, as well as Cldn3 and Cldn5 stain-
ing in their tight junctions responded appropriately to the gain 
or loss of     -catenin activity in these mice. Enhanced staining of 
junctional Cldn3 was also observed in cultured primary mouse 
brain endothelial cells stimulated with Wnt3a ligand. In these 
cells, total Cldn3 protein and mRNA were increased in response 
to Wnt3a in a    -catenin – dependent  manner. Thus,  manipulation 
of the Wnt pathway, at least at the level of    -catenin  stability, 
clearly impacted vessel integrity. 
  It is important to recognize that in addition to mediating 
the transcriptional output from Wnt signaling,    -catenin  also 
functions in cell  –  cell adhesion through its interaction with cad-
herins at the adherens junction (  Brembeck et al., 2006  ). There-
fore, any resulting alterations to the adherens junction complex 
could indirectly impact its close neighbor, the tight junction. 
Moreover, a previous study involving conditional ablation of 
endothelial     -catenin ascribed increased paracellular permea-
bility to defi  cient cell  –  cell contacts (  Cattelino et al., 2003  ). 
Fortunately, there are ways to distinguish the adhesion from the 
signaling activities imparted by     -catenin. With this in mind, 
  Liebner et al. (2008)   showed that the junctional staining of Cldn3 
was greatly diminished in the presence of a dominant interfer-
ing mutant of TCF4, a transcription factor that    -catenin  as-
sociates with to launch gene activation. Conversely, a gain of 
function mutant transcription factor enhanced staining. Consis-
tent with gene activation, the levels of Cldn3 transcript were 
infl  ected by the mutant transcription factors in the expected 
directions. Whether the Cldn3 gene is a direct target of Wnt 
signaling was not pursued, but   Liebner et al. (2008)   strongly 
implicate Wnt signaling in driving its expression. 
  This paper has implications for our understanding and 
treatment of disorders involving the BBB. The study was largely 
focused on the developing brain, and thus any relationship to ge-
netic vascular disorders, particularly those attributable to defec-
tive Wnt pathway genes, would garner attention. Among these, 
familial exudative vitreoretinopathy (FEVR) stands out promi-
nently. FEVR is characterized by incomplete vascularization of 
the retina and was independently linked to defective genes coding 
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have all surfaced as regulators of tight junction proteins, includ-
ing the Cldns ( Hawkins and Davis, 2005 ;  Persidsky et al., 2006 ). 
  Liebner et al. (2008)   now add a well-defi  ned transcriptionally 
active signaling pathway to this understanding. Pathways mod-
ulating Cldns are particularly attractive candidates, as enhanced 
paracellular permeability of the BBB has been reported in 
Cldn5-defi  cient mice (  Nitta et al., 2003  ). Notably, a selective loss 
of Cldn3 at the tight junction has been associated with experi-
mental autoimmune encephalomyelitis in mice, a model of mul-
tiple sclerosis ( Wolburg et al., 2003 ). It should now be of interest 
to reexamine the pathological models involving the BBB in the 
context of Wnt signaling and its manipulation therein. 
  The BBB is of particular interest in the development of 
new therapeutics for degenerative and infl  ammatory diseases of 
the CNS (  Persidsky et al., 2006  ). Retarding the unwanted pas-
sage of leukocytes and water-soluble plasma components into 
the brain will likely require a multifaceted approach, including 
reparation or reinforcement of the tight junction fence. The new 
fi  ndings by   Liebner et al. (2008)   suggest that this might be ac-
complished by therapeutic activation of Wnt signaling in the 
brain. Possible approaches could include activation of the Wnt 
coreceptors LRP5 and LRP6 by R-spondins or by agonistic mono-
clonal antibodies (  Kim et al., 2005  ). Activation of Wnt signal-
ing with small molecule therapeutics is currently approachable 
with inhibitors of glycogen synthase kinase 3 (GSK3). In the 
for Wnt ligand receptors Frizzled 4 (FZD4) and LRP5 (  Robitaille 
et al., 2002  ;   Jiao et al., 2004  ). Norrie disease, also characterized 
by abnormal retinal vasculature, was linked to mutations affect-
ing the secreted protein norrin, which was later identifi  ed as a 
ligand for FZD4 (  Xu et al., 2004  ). Although Wnt signaling is 
clearly implicated in these disorders, the mechanism down-
stream of the ligand  –  receptor interaction is unknown. Consider-
ing the new fi  ndings by   Liebner et al. (2008)  , it is conceivable 
that the impairment in Wnt signaling linked to FVER and Norrie 
disease could lead to inadequate reinforcement of retinal en-
dothelial tight junctions. Interestingly, small hemorrhages were 
noted in the retina and cerebellum of FZD4 
   /     mice, which also 
exhibited high background staining with anti – mouse  IgGs, 
indicative of leaky vasculature (  Xu et al., 2004  ). Accordingly, 
  Liebner et al. (2008)   noted a decrease in retinal vascular perme-
ability induced by ischemia when     -catenin was conditionally 
activated in postnatal mice. 
  Breakdown of both the functional and physical properties 
of the BBB has been implicated in the initiation or exacerbation 
of a host of adult central nervous system (CNS) disorders, includ-
ing multiple sclerosis, Alzheimer ’ s disease, Parkinson ’ s disease, 
cancer, and stroke (  Zlokovic, 2008  ). The physical property of 
the BBB resides at the tight junction complex, but the mechanisms 
underlying its loss of integrity in disease are poorly understood. 
Calcium, G-protein signaling, RhoGTPases, and various kinases 
  Figure 1.       Wnt signaling and the BBB.   Depiction of the primary constituents of the tight junction (TJ) and the adherens junction (AJ) at the interface between 
endothelial cell plasma membranes. Activation of Wnt receptors FZD and LRP5/6 inhibits GSK3 to stabilize     -catenin that in turn enters the nucleus to 
activate T cell factor (TCF)  –  dependent transcription. This drives Cldn3 gene activation either directly or indirectly (dashed line arrow), and the resulting Cldn 
protein reinforces the tight junction. JAM, junctional adhesion molecule.     373 WNT SIGNALING AND THE BLOOD  –  BRAIN BARRIER   • Polakis 
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Wnt pathway, GSK3 phosphorylates     -catenin, thereby mark-
ing it for destruction in the proteosome. Coincidently, GSK3 is 
already a prime target for Alzheimer  ’  s disease, where it hyper-
phosphorylates the Tau protein (  Bhat et al., 2004  ;   Hooper et al., 
2008  ). Strengthening of tight junctions via enhanced Wnt sig-
naling might provide an additional unanticipated benefi  t with 
GSK3 inhibitors in neurodegenerative diseases. This mecha-
nism could in part account for the observed neuroprotective 
effect of a GSK3 inhibitor in a mouse model of hypoxiaischemia 
brain injury (  Cowper-Smith et al., 2008  ). Conversely, transient 
inhibition of Wnt signaling and the ensuing breakdown of the 
tight junction could enable access of therapeutics normally de-
nied by the BBB. Modulation of Cldns in particular might offer 
a unique opportunity because they play a special sieving role in 
gating the passage of blood-borne solutes on the basis of size 
(  Nitta et al., 2003  ). 
  At one level, the proposal by   Liebner et al. (2008)   has 
substantial precedent. The literature is replete with studies pur-
porting a role for Wnt signaling in the development and mainte-
nance of the CNS (  De Ferrari and Moon, 2006  ). However, most 
of these studies relate to direct effects of Wnts and their recep-
tors on the genesis, survival, and morphology of neurons them-
selves and not so much to brain endothelium. Although Wnt 
signaling has also been generously appropriated into vascular 
biology (  Zerlin et al., 2008  ), there is a dearth of studies specifi  -
cally linking it to brain vascularization. The fi  ndings by   Liebner 
et al. (2008)   should now prompt us to consider an endothelial 
component, and in particular the integrity of the tight junction, 
when examining developmental, genetic, or pathological 
outcomes attributable to Wnt signaling in the CNS. FEVR is a 
pertinent example of this. Age-related macular degeneration, 
another vascular disorder of the eye, has also been linked to Wnt 
signaling through polymorphisms in the gene coding for LRP6 
(  Haines et al., 2006  ). Alzheimer  ’  s disease has been linked to 
both hypoactive alleles of LRP6 and to overexpression of the 
secreted Wnt inhibitor dkk1 (  De Ferrari et al., 2007  ;   Caraci 
et al., 2008  ). Moreover, amyloid-     peptide, considered a culprit 
in Alzheimer  ’  s disease, binds to FZD and blocks its activation 
by Wnt (  Magdesian et al., 2008  ). Nearly all of the associations 
of Wnt signaling with neurodegenerative disorders point to a 
defi  ciency in signaling, as does its new association with the in-
tegrity of the tight junction. 
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